Ritter Pharmaceuticals (RTTR) Receiving Somewhat Positive Press Coverage, Report Finds
News stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.6598745795326 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several brokerages have issued reports on RTTR. Zacks Investment Research upgraded shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Thursday, October 26th. Roth Capital set a $2.00 price objective on shares of Ritter Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, HC Wainwright cut their price objective on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating for the company in a research report on Monday, October 23rd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Ritter Pharmaceuticals has a consensus rating of “Buy” and an average price target of $2.92.
Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at $0.35 on Wednesday. Ritter Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). sell-side analysts expect that Ritter Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.